Holen Sie sich die Stockscreener-App
8.85
3.10%
0.29
Schlusskurs vom Vortag:
$8.56
Offen:
$8.5
24-Stunden-Volumen:
453.17K
Relative Volume:
0.32
Marktkapitalisierung:
$878.81M
Einnahmen:
$84.28M
Nettoeinkommen (Verlust:
$-171.30M
KGV:
-5.0941
EPS:
-1.7373
Netto-Cashflow:
$-171.21M
1W Leistung:
+11.01%
1M Leistung:
+6.33%
6M Leistung:
+1.32%
1J Leistung:
-38.97%
1-Tages-Spanne:
$8.465
$8.985
1-Wochen-Bereich:
$7.65
$8.985
52-Wochen-Spanne:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.85 | 850.01M | 84.28M | -171.30M | -171.21M | -1.7373 |
VRTX
Vertex Pharmaceuticals Inc
|
426.31 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.50 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.14 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.46 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.77 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Northland Capital | Outperform |
| 2025-11-04 | Fortgesetzt | Roth Capital | Buy |
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
How The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And Approvals - Yahoo Finance
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
[ARS] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] Eledon Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
[ARS] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] ARS Pharmaceuticals, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals (NASDAQ: SPRY) sets 2026 meeting, highlights neffy launch and cash runway - Stock Titan
[ARS] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] IRONWOOD PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock? - MSN
BlackRock (SPRY) files amendment showing 4.98% ownership - Stock Titan
Epinephrine Nasal Spray Approved for Severe Allergic Reactions in EU - respiratory-therapy.com
Avoiding Lag: Real-Time Signals in (SPRY) Movement - Stock Traders Daily
[ARS] REGENERON PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals Q3 2025 Earnings Preview - MSN
[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
[ARS] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] IONIS PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock? - Yahoo Finance
[ARS] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
FDA Approves Neffy Needle-Free Epinephrine Nasal Spray for Younger Children - respiratory-therapy.com
[ARS] PMV Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] Shuttle Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
[ARS] Verrica Pharmaceuticals Inc. SEC Filing - Stock Titan
FDA Approves Expanded Use for ARS Pharmaceuticals Nasal Spray - HarianBasis.co
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver - Insider Monkey
Pharma-Bio Serv (PBSV) posts $9.0M revenue, margins lift in Europe - Stock Titan
ARS Pharmaceuticals (SPRY) Stock: Breakdown Signals (Nudges Up) 2026-04-16Social Momentum Signals - UBND thành phố Hải Phòng
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - Sahm
neffy® Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions - Investing News Network
Health Canada approves neffy nasal spray for severe allergies By Investing.com - Investing.com Australia
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - Moomoo
Health Canada approves neffy nasal spray for severe allergies - Investing.com
Health Canada Approves neffy Nasal Spray for Anaphylaxis Treatment in Canada, Available Summer 2026 - Quiver Quantitative
neffy® (epinephrine nasal spray) Approved in Canada as the - GlobeNewswire
Discipline and Rules-Based Execution in SPRY Response - Stock Traders Daily
[ARS] Amphastar Pharmaceuticals, Inc. SEC Filing - Stock Titan
Q1 Earnings Forecast for SPRY Issued By Northland Securities - MarketBeat
Rally Mode: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Reactions & Community Trade Idea Sharing Platform - baoquankhu1.vn
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):